A case of steatohepatitis that developed after pancreaticoduodenectomy and progressed rapidly to liver cirrhosis and hepatocellular carcinoma.


Journal

Clinical journal of gastroenterology
ISSN: 1865-7265
Titre abrégé: Clin J Gastroenterol
Pays: Japan
ID NLM: 101477246

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 28 12 2022
accepted: 05 07 2023
medline: 29 9 2023
pubmed: 24 7 2023
entrez: 24 7 2023
Statut: ppublish

Résumé

Steatohepatitis has been reported to occur after pancreaticoduodenectomy (PD). We report a case of steatohepatitis that arose after PD and led to decompensated liver cirrhosis and hepatocellular carcinoma (HCC). A 65-year-old man underwent PD for suspected intraductal papillary mucinous neoplasm. Eight years after PD, he was diagnosed with liver cirrhosis by laboratory tests and computed tomography. Histological examination of liver biopsy revealed hepatic steatosis, inflammation with ballooning of hepatocytes, and fibrosis, indicating nonalcoholic steatohepatitis as the cause of liver cirrhosis. Ten years after PD, he developed HCC and radiotherapy was performed because of impaired liver function. Intrahepatic metastasis appeared subsequently, but no further treatment could be performed due to decompensated liver cirrhosis. Survival time after PD is being prolonged by improvements in imaging studies and therapeutic strategies. Accordingly, we consider that progression to liver cirrhosis and HCC will occur increasingly in cases such as the present patient, which will become a severe problem in long-term post-PD survival. Therefore, it is necessary to clarify the precise mechanism of steatohepatitis after PD and establish appropriate therapeutic strategies.

Identifiants

pubmed: 37486541
doi: 10.1007/s12328-023-01831-9
pii: 10.1007/s12328-023-01831-9
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

715-719

Informations de copyright

© 2023. Japanese Society of Gastroenterology.

Références

El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460–8.
doi: 10.1053/j.gastro.2003.10.065 pubmed: 14762783
Koda M, Kawakami M, Murawaki Y, Senda M. The impact of visceral fat in nonalcoholic fatty liver disease: cross-sectional and longitudinal studies. J Gastroenterol. 2007;42:897–903.
doi: 10.1007/s00535-007-2107-z pubmed: 18008034
Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836–46.
doi: 10.1002/hep.24001 pubmed: 21038418
Nagaya T, Tanaka N, Kimura T, et al. Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy. BBA Clin. 2015;3:168–74.
doi: 10.1016/j.bbacli.2015.02.001 pubmed: 26674248 pmcid: 4661550
Sato T, Matsuo Y, Shiga K, Morimoto M, Miyai H, Takeyama H. Factors that predict the occurrence of and recovery from non-alcoholic fatty liver disease after pancreatoduodenectomy. Surgery. 2016;160:318–30.
doi: 10.1016/j.surg.2016.04.009 pubmed: 27211602
Murata Y, Mizuno S, Kato H, et al. Nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: association of pancreatic exocrine deficiency and infection. Clin J Gastroenterol. 2011;4:242–8.
doi: 10.1007/s12328-011-0226-9 pubmed: 26189528
Kato H, Isaji S, Azumi Y, et al. Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: proposal of a postoperative NAFLD scoring system. J Hepatobiliary Pancreat Sci. 2010;17:296–304.
doi: 10.1007/s00534-009-0187-2 pubmed: 19809782
Sato R, Kishiwada M, Kuriyama N, et al. Paradoxical impact of the remnant pancreatic volume and infectious complications on the development of nonalcoholic fatty liver disease after pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci. 2014;21:562–72.
doi: 10.1002/jhbp.115 pubmed: 24824077
Ohgi K, Okamura Y, Yamamoto Y, et al. Perioperative computed tomography assessments of the pancreas predict nonalcoholic fatty liver disease after pancreaticoduodenectomy. Medicine (Baltimore). 2016;95: e2535.
doi: 10.1097/MD.0000000000002535 pubmed: 26871772 pmcid: 4753867
Satoi S, Sho M, Yanagimoto H, et al. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreatic cancer? A randomized controlled trial. J Hepatobiliary Pancreat Sci. 2016;23:167–73.
doi: 10.1002/jhbp.318 pubmed: 26748629
Luu C, Thapa R, Rose T, et al. Identification of nonalcoholic fatty liver disease following pancreatectomy for noninvasive intraductal papillary mucinous neoplasm. Int J Surg. 2018;58:46–9.
doi: 10.1016/j.ijsu.2018.09.002 pubmed: 30218781 pmcid: 7771269
Okabe H, Yamashita YI, Inoue R, et al. Postoperative nonalcoholic fatty liver disease is correlated with malnutrition leading to an unpreferable clinical course for pancreatic cancer patients undergoing pancreaticoduodenectomy. Surg Today. 2020;50:193–9.
doi: 10.1007/s00595-019-01866-x pubmed: 31463596
Yasukawa K, Shimizu A, Yokoyama T, et al. Preventive effect of high-dose digestive enzyme management on development of nonalcoholic fatty liver disease after pancreaticoduodenectomy: a randomized controlled clinical trial. J Am Coll Surg. 2020;231:658–69.
doi: 10.1016/j.jamcollsurg.2020.08.761 pubmed: 32927075
Nagai M, Sho M, Satoi S, et al. Effects of pancrelipase on nonalcoholic fatty liver disease after pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci. 2014;21:186–92.
doi: 10.1002/jhbp.14 pubmed: 23798362
Maeda S, Wada H, Tanemura M, et al. A case of hepatocellular carcinoma treated by transcatheter arterial chemoembolization and hepatectomy after subtotal stomach preserving pancreaticoduodenectomy for duodenal cancer. Gan To Kagaku Ryoho. 2012;39:1988–90.
pubmed: 23267952
Yoshioka R, Tomimaru Y, Noguchi K, et al. A Resected case of intraductal pupillary mucinous neoplasm of the pancreas characterized by recurrence in the remnant pancreas and multiple malignant neoplasms in other organs. Gan To Kagaku Ryoho. 2016;43:1782–4.
pubmed: 28133130

Auteurs

Hirono Owa (H)

Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.

Kazushi Sugimoto (K)

Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.

Masahiko Tameda (M)

Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. tameda@med.mie-u.ac.jp.

Suguru Ogura (S)

Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.

Masashi Kishiwada (M)

Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Japan.

Hiroto Yuasa (H)

Department of Pathology, Mie University Graduate School of Medicine, Tsu, Japan.

Yuji Kozuka (Y)

Department of Pathology, Mie University Graduate School of Medicine, Tsu, Japan.

Hayato Nakagawa (H)

Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH